TOP-5 Analyst Price Targets as of 04.05.26
Reading Time: 3 minutes
Compass Pathways [US20451W1018] Jefferies initiates coverage with "Buy" and a price target of 18 USD (100% upside potential) The analysts express unusually strong confidence, seeing a 75–85% likelihood that the US FDA will approve COMP360, an oral psilocybin for the treatment of treatment-resistant depression, in fiscal year 2026. Furthermore, Jefferies considers the market launch prospects to be very favorable, as COMP360 is expected to be the first approved psychedelic on the market, which should significantly enhance public perception and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
